St.Paul, Minnesota-based St. Jude Medical (NYSE:STJ) announced Wednesday that the Food & Drug Administration has approved a new pericardial aortic stented tissue valve — the Trifecta. In a statement, the company said that the Trifecta valve was designed to optimize the flow of blood through the valve and for long-term durability. To ensure the structural […]
Andover Healthcare Inc. pulls its compression bandage system off the market in the face of a legal move by 3M Co. to enforce a recently won patent. 3M Co. (NYSE:MMM) forced a compression bandage system made by Andover Healthcare Inc. off the market by threatening to seek a legal injunction barring sales of the product. […]
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
State Rep. Tim Mahoney, DFL-St. Paul, wants the state Legislature to pour millions of dollars into a state Science and Technology Authority created last year.
LifeScience Alley, a Minnesota trade association representing medical technology companies, has circulated an inaccurate document about licensing and commercialization at the Minnesota Partnership for Bioscience and Medical Genomics.
The Minnesota make of new innovative medical devices saw its fourth-quarter profits increase 8.9 percent compared to the previous year's fourth quarter. St. Jude said it expects adjusted, consolidated Q1 net earnings in the range of 77 cents to 79 cents per; full-year adjusted, consolidated EPS are forecast to be between $3.25 and $3.30
St. Jude Medical says it's won approval to begin selling its Athena deep brain stimulation programming device Down Under.
Two months after it announced a development agreement with an up-and-coming ultrasound technology company, St. Jude Medical (NYSE:STJ) has launched a faster, more portable intracardiac ultrasound system designed for taking images inside the heart. The ViewMate Z combines St. Jude's intracardiac echocardiography (ICE) catheter with California-based Zonare’s top-rated z.one Convertible Ultrasound system.
On the heels of FDA approval of its new anti-spasticity drug Gablofen, CNS Therapeutics has raised $3 million in equity, according to documents filed with the Securities and Exchange Commission.
Life science current events will collide with political realities in Minnesota. Last year the medical industry made important strides, including winning an angel investment tax credit. This year healthcare interests will likely be on the defensive. The University of Minnesota, the Biomedical Discovery District and health services for the poor are on the chopping block.
3M Co. sues Andover Healthcare Inc. for allegedly infringing on patents related to the company’s two-layer compression bandage systems. 3M Co. (NYSE:MMM) is suing Salisbury, Mass.-based Andover Healthcare Inc. for patent infringement. The company alleges that Andover’s two-layer compression bandage systems, including its CoFlex TLC and the CoFlex TLC Lite, infringe upon patents that cover […]
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
A stronger market for its diagnostic systems and an emphasis on sales and marketing sent Angeion Corp.'s (NASDAQ:ANGN) fourth-quarter earnings into the black. It's been a rough year (actually, last several years) for the company, having survived the threat of a proxy battle and the termination of its CFO, but credit Angeion for ending on a strong note.
With less than four weeks left in the year, Minnesota has awarded about 38 percent of the $11-million worth of angel investor tax credits available for 2010. Since launching the program in July, the state has granted about $4 million in tax credits to investors who funded startups ranging from solar energy to drugs to cancer treatments and diabetes, according to figures released this week by the Department of Employment and Economic Development.
The incoming Republican leadership in the Minnesota state legislature already is making good on its promises to streamline government. Last month, GOP officials unveiled a significantly slimmer committees structure, designed to eliminate redundancy and speed the notoriously slow business of making policy and passing laws. One casualty of the slimmer structure will be The House Committee on Biosciences and Workforce Development.
Synovis Life Technologies Inc. (NASDAQ:SYNO) may not have generated many headlines this year (which is not necessarily a bad thing), but the St. Paul company has quietly produced a rather impressive annual performance, especially compared to what remains of Minnesota's shrinking, publicly traded medical device sector.
Dale Wahlstrom is an optimistic guy. But budget-cutting Republicans poised to control the House and Senate, and possibly the governor's office next year may test the optimism of the BioBusiness Alliance of Minnesota CEO.